FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048805209> ?p ?o ?g. }

• W3048805209 endingPage "A120" @default.
• W3048805209 startingPage "A120" @default.
• W3048805209 abstract "Abstract Background: Sex differences in non-small cell lung cancer (NSCLC) outcomes have been described. Immune-related adverse events (IRAEs) have emerged as a serious clinical problem in the use of immune checkpoint inhibitors (ICI). Risk factors for IRAEs and their association with response to therapy remain controversial. Sex differences in innate and adaptive immune responses have been observed but the association of these differences with IRAEs remains unclear. Therefore, we studied sex differences in IRAEs and their association with response to therapy. Methods: All patients with metastatic NSCLC treated with anti-PD1 and anti-PDL1 therapy at Mayo Clinic Rochester and Florida from 2015 to 2018 were reviewed. Patients receiving treatment at an outside facility with history autoimmune disorders or radiation-induced pneumonitis were excluded. Chi-square test was used to estimate differences in categorical data. Kaplan-Meier method was used for time-to-event analysis. Results: A total of 231 patients were identified; 120 (52%) were women and 111 (48%) were men. Baseline characteristics and ICI distribution were similar among groups. Women were more likely to experience IRAEs compared to men (48% vs. 31%, p&lt;0.008). Among patients with IRAEs, women were more likely to be prescribed systemic steroids (63% vs. 41%, p&lt;0.02). On the other hand, no significant differences were observed in the administration of intravenous steroids. Women were more likely to develop pneumonitis (23% vs. 12%, p&lt;0.03) and arthralgias (17% vs. 3%, p&lt;0.04). However, dermatologic toxicities (35% vs. 9%, p&lt;0.002) were more commonly seen in men. In 17% of women the ICI was discontinued due to toxicity (men 7%). Besides sex, no other clinical characteristic was associated with increased IRAEs. Women with IRAEs were more likely to have a radiographic response compared with women without IRAEs (78% vs. 23%, p&lt;0.0001), although this was not observed in men (37% vs. 26%, p&gt;0.22). Better PFS was observed in women with IRAEs (10 months vs. 3.3 months, p&lt;0.0006) compared to women without IRAEs. Conclusions: Women with metastatic NSCLC are more likely to experience IRAEs compared to men. We also observed sex differences in the frequency of certain IRAEs. In addition, an association between IRAEs and response to therapy was observed in women. Larger studies are needed to investigate the mechanisms underlying these associations. Citation Format: Narjust Duma, Abdel-Ghani Azzouqa, Siddhartha Yadav, Kahterine Hoversten, Clay Reed, Andrea Sitek, Elizabeth Enninga, Jonas Paludo, Lisa Kottschade, Aaron Mansfield, Rami Manochakian, Roxana Dronca, Alex Adjei. Sex differences in tolerability and response to immune checkpoint inhibitors in non-small cell lung cancer patients [abstract]. In: Proceedings of the Eleventh AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2018 Nov 2-5; New Orleans, LA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl):Abstract nr A120." @default.
• W3048805209 created "2020-08-18" @default.
• W3048805209 creator A5008583422 @default.
• W3048805209 creator A5016469101 @default.
• W3048805209 creator A5025231747 @default.
• W3048805209 creator A5027176998 @default.
• W3048805209 creator A5036662227 @default.
• W3048805209 creator A5041114807 @default.
• W3048805209 creator A5067707171 @default.
• W3048805209 creator A5068046530 @default.
• W3048805209 creator A5075616806 @default.
• W3048805209 creator A5076652343 @default.
• W3048805209 creator A5078812195 @default.
• W3048805209 creator A5085731361 @default.
• W3048805209 creator A5087757839 @default.
• W3048805209 date "2020-06-01" @default.
• W3048805209 modified "2023-10-04" @default.
• W3048805209 title "Abstract A120: Sex differences in tolerability and response to immune checkpoint inhibitors in non-small cell lung cancer patients" @default.
• W3048805209 doi "https://doi.org/10.1158/1538-7755.disp18-a120" @default.
• W3048805209 hasPublicationYear "2020" @default.
• W3048805209 type Work @default.
• W3048805209 sameAs 3048805209 @default.
• W3048805209 citedByCount "0" @default.
• W3048805209 crossrefType "journal-article" @default.
• W3048805209 hasAuthorship W3048805209A5008583422 @default.
• W3048805209 hasAuthorship W3048805209A5016469101 @default.
• W3048805209 hasAuthorship W3048805209A5025231747 @default.
• W3048805209 hasAuthorship W3048805209A5027176998 @default.
• W3048805209 hasAuthorship W3048805209A5036662227 @default.
• W3048805209 hasAuthorship W3048805209A5041114807 @default.
• W3048805209 hasAuthorship W3048805209A5067707171 @default.
• W3048805209 hasAuthorship W3048805209A5068046530 @default.
• W3048805209 hasAuthorship W3048805209A5075616806 @default.
• W3048805209 hasAuthorship W3048805209A5076652343 @default.
• W3048805209 hasAuthorship W3048805209A5078812195 @default.
• W3048805209 hasAuthorship W3048805209A5085731361 @default.
• W3048805209 hasAuthorship W3048805209A5087757839 @default.
• W3048805209 hasConcept C121608353 @default.
• W3048805209 hasConcept C126322002 @default.
• W3048805209 hasConcept C143998085 @default.
• W3048805209 hasConcept C197934379 @default.
• W3048805209 hasConcept C203014093 @default.
• W3048805209 hasConcept C2776256026 @default.
• W3048805209 hasConcept C2777714996 @default.
• W3048805209 hasConcept C2778375690 @default.
• W3048805209 hasConcept C2779524853 @default.
• W3048805209 hasConcept C71924100 @default.
• W3048805209 hasConcept C8891405 @default.
• W3048805209 hasConceptScore W3048805209C121608353 @default.
• W3048805209 hasConceptScore W3048805209C126322002 @default.
• W3048805209 hasConceptScore W3048805209C143998085 @default.
• W3048805209 hasConceptScore W3048805209C197934379 @default.
• W3048805209 hasConceptScore W3048805209C203014093 @default.
• W3048805209 hasConceptScore W3048805209C2776256026 @default.
• W3048805209 hasConceptScore W3048805209C2777714996 @default.
• W3048805209 hasConceptScore W3048805209C2778375690 @default.
• W3048805209 hasConceptScore W3048805209C2779524853 @default.
• W3048805209 hasConceptScore W3048805209C71924100 @default.
• W3048805209 hasConceptScore W3048805209C8891405 @default.
• W3048805209 hasIssue "6_Supplement_1" @default.
• W3048805209 hasLocation W30488052091 @default.
• W3048805209 hasOpenAccess W3048805209 @default.
• W3048805209 hasPrimaryLocation W30488052091 @default.
• W3048805209 hasRelatedWork W1556562895 @default.
• W3048805209 hasRelatedWork W1967103478 @default.
• W3048805209 hasRelatedWork W2032912323 @default.
• W3048805209 hasRelatedWork W2087016115 @default.
• W3048805209 hasRelatedWork W2160729253 @default.
• W3048805209 hasRelatedWork W2349164817 @default.
• W3048805209 hasRelatedWork W2363981502 @default.
• W3048805209 hasRelatedWork W2372561159 @default.
• W3048805209 hasRelatedWork W2375344515 @default.
• W3048805209 hasRelatedWork W2390152934 @default.
• W3048805209 hasVolume "29" @default.
• W3048805209 isParatext "false" @default.
• W3048805209 isRetracted "false" @default.
• W3048805209 magId "3048805209" @default.
• W3048805209 workType "article" @default.